To evaluate the combination of docetaxel and ZD1839 on pathologic complete response (pCR) in radical prostatectomy specimens. Pathological complete response is defined as no microscopic evidence of neoplastic cells in the resected specimen.
Evaluate the toxicity of docetaxel and ZD1839 in patients with high risk, locally advanced prostate carcinoma prior to surgical resection
(and 2 more...)
18 Years and older (Adult, Senior)
BRI 8847 GIA #16134 1839US/290 IIT# 16134
October 21, 2005
February 7, 2012
Virginia Mason Medical Center Seattle, Washington, United States
† Study has passed its completion date and status has not been verified in more than two years.